Skip to main content
Novartis
language-selector-globe
Choose Location
  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
Argentina | Español
Brazil | Português
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Mexico | Español
United States | English
Australia | English
Bangladesh | English
Hong Kong S.A.R. | 繁體中文
India | English
Indonesia | English
Japan | 日本語
Korea | 한국어
Mainland China | 中文
Malaysia | English
Pakistan | English
Philippines | English
Singapore | English
Taiwan | 繁體中文
Thailand | ภาษาไทย
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Bulgaria | Български
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hungary | Magyar
Ireland | English
Italy | Italiano
Latvia | Latvian
Lithuania | Lithuanian
Netherlands | Nederlands
Norway | Norsk
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Serbia | Srpski
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Türkiye | Türkçe
United Kingdom | English
Global | English
Novartis Foundation | English(link is external)
Egypt | English
Israel | עברית
Saudi Arabia | العربية
South Africa | English
language-selector-globe
Choose Location
Americas Asia Pacific Europe International Middle East & Africa
Argentina | Español
Australia | English
Austria | Deutsch
Bangladesh | English
Belgium | Français
Belgium | Nederlands
Brazil | Português
Bulgaria | Български
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Egypt | English
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hong Kong S.A.R. | 繁體中文
Hungary | Magyar
India | English
Indonesia | English
Ireland | English
Israel | עברית
Italy | Italiano
Japan | 日本語
Korea | 한국어
Latvia | Latvian
Lithuania | Lithuanian
Mainland China | 中文
Malaysia | English
Mexico | Español
Netherlands | Nederlands
Norway | Norsk
Global | English
Novartis Foundation | English(link is external)
Pakistan | English
Philippines | English
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Saudi Arabia | العربية
Serbia | Srpski
Singapore | English
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
South Africa | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Taiwan | 繁體中文
Thailand | ภาษาไทย
Türkiye | Türkçe
United Kingdom | English
United States | English
    • About 

      Team meeting
      About

      Every day, we work to reimagine medicine to improve and extend people’s lives. Learn about us and our story.

      • Novartis in the US 
      • People and culture 
      • Products 
      • Therapeutic areas 
      • Inclusion and belonging 
      • Contact us 
    • Patients and caregivers 

      • Novartis commitment to patients and caregivers 
      • Patient assistance 
      • Diseases 

        • Chronic spontaneous urticaria (CSU) 
        • Hidradenitis suppurativa (HS) 
        • Prostate Cancer (PC) 
        • Paroxysmal Nocturnal Hemoglobinuria (PNH) 
        • Breast Cancer 
        • Sjögren's Disease 
      • Participating in clinical trials 
      • Adverse event reporting 
      • Patient resources 
      Patient smiling at doctor image
      Patients and caregivers

      Visit resources tailored for our patient communities and their caregivers, including information around patient assistance, disease information and related resources.

    • Healthcare professionals 

      • Novartis pipeline 
      • Novartis clinical trials 
      • Adverse event reporting 
      • External funding 
      • HCP resources 
      • Personalized and Precision Medicine 
      • Health Information Technology Resources 
      Two doctors examining X-ray
      Healthcare professionals

      Visit our resource hub for information around clinical trials, our products and innovation pipeline.

    • ESG 

      • Ethical behavior 

        • Code of ethics 
        • SpeakUp 
        • PhRMA Code on interactions with healthcare professionals 
        • Business principles 
      • Ethics, risk and compliance 

        • Pay transparency-EPIC 
        • Compliance program 
        • State laws 
        • Corporate integrity agreement 
        • Payments to HCPs & HCOs 
        • Drug Supply Chain Security Act Information 
      • Corporate responsibility 

        • Novartis in Society Integrated Report 
        • Novartis US Foundation 
        • People and communities 
        • Beacon of hope 

      • Environmental sustainability 
      Family and friends party at home
      ESG

      Learn about our commitment to making a positive impact on society through innovative medicine access, sustainability, and governance.

    • News 

      • News archive 
      • Statements 
      • Stories 
      • Contacts 
      Co-workers having a meeting
      News

      Check out our media hub for the latest news, stories, and updates from across our business.

    • Careers 

      • Career search 
      • Early career 
      • Employee benefits 
      • Inclusion and belonging  
      Colleagues laughing
      Careers

      Check out what careers are available at Novartis in the U.S. and learn about our people and culture.

    Grandmother, mother and daughter smiling and laughing on a beach
    Home

    Working together, we can reimagine medicine to improve and extend people’s lives.

Tags Archive Navigation
  • All
    • Careers
    • Feature News
    • In the News
    • Media Releases
    • Story
icon
  • Products
    Jadenu® (deferasirox)
  • Products
    Tabrecta® (capmatinib)
  • Products
    Piqray® (alpelisib)
  • Products
    Mayzent® (siponimod)
  • Products
    Zykadia® (ceritinib)
  • Products
    Egaten® (triclabendazole)
  • Products
    Diovan® (valsartan)
  • Products
    Kisqali® (ribociclib)
  • Products
    Mekinist® (trametinib)
  • Products
    Promacta® (eltrombopag)
  • Products
    Coartem® (artemether/ lumefantrine)
  • Products
    Gleevec® (imatinib mesylate)

Pagination

  • ‹ Previous page
  • 1
  • 2
  • › Next page

Novartis United States

Navigate Novartis
  • Patients & caregivers
  • Healthcare professionals
  • ESG
  • News
  • Careers
Media center
  • News archive
  • Statements
  • Stories
Our portfolio
  • Novartis clinical pipeline
  • Novartis product portfolio
Other Novartis US websites
  • Oncology HCP resources
  • Medical information(link is external)
  • Global site
  • (link is external)
  • (link is external)
  • (link is external)
  • (link is external)
  • (link is external)
Footer Bottom
© 2025 Novartis Pharmaceuticals Corporation
  • Terms of use
  • Privacy policy
  • Consumer health privacy policy
  • Contacts
  • Site map
  • Web accessibility
Novartis Site Directory
This site is intended for US residents only